Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: Expression of CD55 mRNA and protein in normal thymus, thymoma, and TSCC. The expression levels of CD55 mRNA ( A ) and protein ( B ) were significantly elevated progressively in normal thymus tissue, thymoma, and TSCC

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Expressing

Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: Intensities of CD55 expression in TETs (IHC) scored 0: negative expression ( A , 40×; a, 200×); scored 1: low expression ( B , 40×; b, 200×); scored 2: moderate expression ( C , 40×; c, 200×); scored 3: high expression ( D , 40×; d, 200×)

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Expressing

Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: Proportion of CD55 expression in TETs (IHC) scored 0: negative expression ( A , 40×; a, 200×); scored 1: 1% − 30% positive cells ( B , 40×; b, 200×); scored 2: 30% − 60% positive cells ( C , 40×; c, 200×); scored 3: ≥ 60% positive cells ( D , 40×; d, 200×)

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Expressing

Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: Kaplan-Meier Survival Analysis in TETs The results demonstrated that PFS of TETs was closely related to CD55 mRNA ( A , p < 0.0001), CD55 protein ( B , p < 0.0001), tumor completeness of resection ( C , p < 0.0001), histological type ( D , p < 0.0001), Masaoka-Koga stage ( E , p < 0.0001), and adjuvant therapy ( F , p = 0.0009), but no with gender ( G , p = 0.1805) or MG ( H , p = 0.7269)

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Adjuvant

Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: The relationship between CD55 and the clinical pathological features of patients The expression levels of CD55 mRNA and protein were higher in R1/R2 group ( A ), higher histological grade ( B ), Masaoka-Koga stage III/IV ( C ), adjuvant therapy ( D ) compared with the corresponding R0 group, normal thymus tissues, and stage I/II, and no-adjuvant therapy. Moreover, the expression of CD55 protein was significantly higher expressed in ≥ 60 years compared with ˂60 years ( E ). Additionally, CD55 protein expression was higher in males than that in females ( F ), whereas CD55 mRNA did not show similar results ( E, F ). Patients without MG showed higher CD55 mRNA and protein expression levels than those with MG, however, this difference was not statistically significant ( G ). There was also no statistically significant relationship between tumor diameter and CD55 expression ( H ). When CD55 protein was highly expressed, the mRNA level was also high ( I ).

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Expressing, Adjuvant

Journal: World Journal of Surgical Oncology

Article Title: CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

doi: 10.1186/s12957-025-04051-2

Figure Lengend Snippet: Kaplan-Meier Survival Analysis in high-risk TETs The results demonstrated that PFS of high-risk TETs was closely related to high expression of CD55 mRNA (A, p < 0.0001) and CD55 protein (B, p = 0.0168)

Article Snippet: The primary rabbit anti-human CD55 polyclonal antibody (Proteintech, USA) was diluted at a ratio of 1:1400.

Techniques: Expressing

Journal: Journal of Neuroinflammation

Article Title: Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

doi: 10.1186/s12974-024-03234-0

Figure Lengend Snippet: Exercise training suppressed complement C3 and C1q levels and inhibited complement-induced phagocytic function of microglia. Level of serum C3 ( a ) (Sham group n = 6, PFFs group n = 5, Exer group n = 7) and C1q ( b ) (Sham group n = 5, PFFs group n = 7, Exer group n = 7) concentration measured by Elisa. The correlation of latency of rotarod test and serum C3 ( c ) and C1q ( d ) concentration. e Western blot showing the expression of TH protein and complement C3α in the substantia nigra. (n = 6 per group) f Western blot showing the expression of TH protein and complement C3α in the striatum. (n = 6 per group) g Immunofluorescence results and relative quantitative analysis of C1q and microglia co-localization in the striatum. Scale bar = 20 μm. (n = 20 per group from 4 mice each group) h Level of DA concentration measured by Elisa in the striatum. i Western blot showing the expression of CD55 protein in the striatum. (n = 6 per group) All data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA

Article Snippet: CD55 , Proteintech , 26580-1-AP , WB1:1000 , AB_2880559.

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Immunofluorescence

Journal: Journal of Neuroinflammation

Article Title: Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

doi: 10.1186/s12974-024-03234-0

Figure Lengend Snippet: Behavioral and pathological evaluation of AAV treatment experiment. a The latency time of the rotarod test and pole test in Sham, PFFs, and CD55-OE groups over time and at day21. (Sham group n = 8, PFFs group n = 7, CD55-OE group n = 11) b Time of the pole test in the three groups over time and at day21. (Sham group n = 9, PFFs group n = 8, CD55-OE group n = 11) c Results of western blot for the expression of CD55 and complement C3α in the striatum. (n = 6 per group) d Results of western blot for the expression of TH protein in the substantia nigra and striatum. (n = 6 per group) e Results of western blot for the expression of PSD95 protein in the striatum and spine density count in the striatum. (n = 6 per group) (n = 18 per group from 3 mice each group) f Changes in microglial states and synaptic engulfment function in the striatum among Sham, PFFs, and CD55-OE groups. Scale bar = 10 μm. (n = 15 per group from 3 mice each group) (n = 3per group) All data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA

Article Snippet: CD55 , Proteintech , 26580-1-AP , WB1:1000 , AB_2880559.

Techniques: Western Blot, Expressing

Journal: Journal of Neuroinflammation

Article Title: Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

doi: 10.1186/s12974-024-03234-0

Figure Lengend Snippet: Behavioral and pathological evaluation of AAV pre-treatment experiment. a The latency time of the rotarod test and pole test in Sham, PFFs, and CD55-OE groups over time and at day21. (Sham group n = 7, PFFs group n = 6, CD55-OE group n = 8) b Time of the pole test in the three groups over time and at day21. (Sham group n = 8, PFFs group n = 6, CD55-OE group n = 7) c Results of western blot for the expression of CD55 and complement C3α in the striatum. (n = 5 per group) d Results of western blot for the expression of TH protein in the substantia nigra and striatum. (n = 5 per group) e Results of western blot for the expression of PSD95 protein in the striatum and spine density count in the striatum. (n = 5 per group) (n = 18 per group from 3 mice each group) f Changes in microglial states and synaptic engulfment function in the striatum among Sham, PFFs, and CD55-OE groups. Scale bar = 10 μm. (n = 15 per group from 3 mice each group) (n = 3per group) All data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA

Article Snippet: CD55 , Proteintech , 26580-1-AP , WB1:1000 , AB_2880559.

Techniques: Western Blot, Expressing

Journal: Journal of Neuroinflammation

Article Title: Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

doi: 10.1186/s12974-024-03234-0

Figure Lengend Snippet: Proteomics analysis of CD55-OE-AAV pre-treatment group revealed the protective effects of CD55 and potential shared pathways between CD55-AAV overexpression and exercise intervention. a PCA analysis of Sham, PFFs and CD55-OE groups. b Volcano plot of DE Proteins between pairs of groups. c Results of “complement activation pathway” from GSEA of three groups. d Different expression module of three groups and relative pathway enrichment. e Exercise and CD55-OE-AAV common up-regulated GSEA pathway. f Exercise and CD55-OE-AAV common down-regulated GSEA pathway

Article Snippet: CD55 , Proteintech , 26580-1-AP , WB1:1000 , AB_2880559.

Techniques: Over Expression, Activation Assay, Expressing

Journal: Journal of Neuroinflammation

Article Title: Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

doi: 10.1186/s12974-024-03234-0

Figure Lengend Snippet:

Article Snippet: CD55 , Proteintech , 26580-1-AP , WB1:1000 , AB_2880559.

Techniques:

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: CD55 protein localizes in the nucleus of human ovarian cancer cells. ( A ) Generation of A2780 cancer stem cells from A2780 ovarian cancer cells using an established NANOG-GFP reporter system. Cancer stem cells were injected into NSG mice and tumors harvested at necropsy and fixed for FFPE analysis. ( B ) Tumor specimen from A2780 CSCs non-targeted control (NT), shRNA#1 and shRNA#2 were processed for hematoxylin & eosin (H&E) and immunohistochemical analysis for CD55. Yellow arrowheads denote CD55 nuclear staining. ( C ) Human ovarian tumor specimen (Clear cell carcinomas and Endometrioid ovarian carcinoma) collected and fixed. ( D ) Hematoxylin and eosin staining, and CD55 immunohistochemistry were performed. Yellow arrowheads denote CD55 nuclear staining. ( E, F ) CD55 protein expression in ascites cells from chemoresistant OC patients. CCF OC45, CCF OC61 and CCF OC88 ascites cells cultured, harvested, and lysed for immunoblot analysis of CD55. ( G ) CCF OC45, CCF OC61 and CCF OC88 cells were harvested, fractionated for nuclear and cytoplasmic pools, and immunobloted for CD55. Lamin A/C and tubulin used as nuclear and cytoplasmic loading controls, respectively

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Injection, Control, shRNA, Immunohistochemical staining, Staining, Immunohistochemistry, Expressing, Cell Culture, Western Blot

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: Cell surface CD55 is enriched in the nucleus of chemoresistant ovarian cancer cells. ( A ) A2780, CP70, and SKOV3 ovarian cancer (OC) were analyzed by immunofluorescence (IF) for CD55 protein localization. After fixation, cells were treated either with or without a permeabilizing agent (Triton X-100), followed by IF processing using a CD55 antibody. The cells were then counterstained with DAPI to visualize the nucleus. Cell surface CD55 expression is indicated with arrowhead and nuclear CD55 with an arrow. ( B, C ) Platinum sensitive (Designated as S) and resistant (Designated as R) ovarian cancer cells were lysed and whole cell, cytoplasmic, and nuclear fractions isolated followed by SDS-PAGE and immunoblotting for CD55 protein. Lamin A/C and Tubulin were used as nuclear and cytoplasmic marker respectively. ( D ) HEK293 and Jurkat cells were fractionated to enrich cytoplasmic and nuclear compartments, resolved by SDS-PAGE, and blotted for CD55. Lamin A/C was used as nuclear marker and Tubulin was used as cytoplasmic marker. ( E ) HEK293 cells were grown on coverslips, fixed with paraformaldehyde, treated with/without permeabilizing agent (Triton X-100) followed by IF for CD55. DAPI counterstaining was used to detect the nuclei. ( F ) Cytoplasmic and nuclear expression of CD59, a GPI-anchored protein in CP70 cells. ( G ) CP70 cells were treated with cycloheximide (50 µg/ml) for 0, 1, 3, and 6 h, followed by cell fractionation for cytoplasmic and nuclear isolation. Samples separated on SDS-PAGE followed by western blotting for CD55 protein expression corrected to 0 time point. Percentage of CD55 expression relative to initial CD55 protein are presented (Blots shown in supplementary Fig. I). Tubulin and lamin A/C immunoblots show relative enrichment of cytoplasmic and nuclear fractions respectively

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Immunofluorescence, Expressing, Isolation, SDS Page, Western Blot, Marker, Cell Fractionation

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: Nuclear CD55 is glycosylated and originates from the cell surface. ( A ) Cytoplasmic and nuclear proteins from ovarian cancer cells were fractionated. Fractionated proteins were then treated with protein deglycosylation mix II enzyme to remove glycosylation from CD55 proteins. Protein samples were processed for immunoblot analysis. ( B ) Ovarian cancer cells (OV81 and CP70) were subjected to 24-hour tunicamycin treatment. Subsequently, cytoplasmic, and nuclear proteins were fractionated, and CD55 protein expression was assessed through immunoblot analysis. ( C ) PIPLC treatment strategy to shed surface CD55 protein. ( D, E , and F ) CP70 cells were treated with increasing dose of PIPLC (0, 10, 25, 35 Unit/ml) at 37 °C for 2, 8, and 12 h. At indicated times, cells were harvested and fractionated, followed by separation by SDS-PAGE and CD55 immunoblotting. The resulting blots were quantified using Image J software. Data are representative of an experiment that was repeated 3 times

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Glycoproteomics, Western Blot, Expressing, SDS Page, Software

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: CD55 S/T domain binds chromatin and drives cell proliferation, CSC frequency, and cisplatin resistance. ( A ) Wild type CD55 and domain deletion mutants were engineered and cloned into lentiviral vector, pLenti CMV Puro DEST. Lentiviruses were transduced into CD55 CRISPR KO CP70 cells and stable cell lines generated. Cells were cultured and fractionated to obtain cytoplasmic and nuclear pools. Cytoplasmic and nuclear fractions were separated on SDS-PAGE and immunoblotted for CD55 (Blots shown in supplementary Fig. A). Summary of findings displayed as either positive (+) or negative (-) for nuclear localization. ( B ) Immunofluorescence analysis of CD55 OE, ΔST, and Δ1234 (S/T only) transduced CP70 cells. CD55 protein localization was shown in red color. Nucleus was counter stained with DAPI (Blue). ( C ) CD55 immunoblot of CD55 OE, ΔST, and Δ1234 transduced CP70 KO cells. LaminA/C was used as loading control for nuclear fraction and Tubulin was used as a control for cytoplasmic fraction. ( D ) Cell proliferation analysis using Incucyte. KO, OE, and mutants ΔST, Δ1234 were analyzed over a 4-day period. ( E ) Stem cell frequency in tumorspheres was analyzed by limiting dilution assay. One way ANOVA was performed, and Tukey’s multiple comparison test was performed to determine p values (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). ( F ) Cisplatin sensitivity assay of OE, KO, and mutants ΔST, Δ1234 transduced CP70 cells. Data was analyzed with GraphPad Prism and IC 50 values are indicated in parentheses. ( G ) CP70 parental and ∆1234 cells were harvested and cytosolic, membrane, soluble nuclear, and chromatin bound protein fractions were analyzed by immunoblot for CD55. Tubulin (Cytosolic), Na + /K + ATPase (Membrane), Histone 3 (Chromatin) and Lamin AC (Nuclear) were used as loading markers for each fraction

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Clone Assay, Plasmid Preparation, CRISPR, Stable Transfection, Generated, Cell Culture, SDS Page, Immunofluorescence, Staining, Western Blot, Control, Limiting Dilution Assay, Comparison, Sensitive Assay, Membrane

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: CD55 nuclear localization accelerates tumor growth and induce chemoresistance. ( A ) CP70 CD55 KO, OE, ∆1234, ∆S/T cells were intraperitoneally injected into NSG mice. Once tumors were detected, mice were randomized into either saline (Veh) or cisplatin (2 mg/kg) twice weekly. ( B , C , D , E ) Representative bioluminescence images of 3 tumor bearing mice from each cohort at 11, 25, and 39 days of the treatment in (B) OE cohort (C), KO cohort (D), ∆1234 cohort and (E) ∆S/T cohort. ( F ) Tumor growth kinetics of KO vs. OE mice treated with cisplatin or veh. ( G ) Tumor growth kinetics of ∆1234 vs. ∆ST mice treated with cisplatin or veh. ( N = 9 mice/treatment). ( H ) Tumor FFPE sections from Veh treated KO, OE, ∆S/T and ∆1234 mice were analyzed for apoptosis (TUNEL assay), cell proliferation (Ki-67 immunohistochemistry, and H&E staining. ( I ) Tumor FFPE sections from Cisplatin treated KO, OE, ∆S/T and ∆1234 mice were analyzed for apoptosis (TUNEL assay), cell proliferation (Ki-67 immunohistochemistry, and H&E staining. ( J ) Analysis of Ki-67 positive cells in FFPE sections from KO, OE, ∆S/T and ∆1234 mice. Representative data from 5 different fields of Ki-67 FFPE section of each treatment group. ( K ) Analysis of TUNEL positive cells in FFPE sections from KO, OE, ∆S/T and ∆1234 mice. Representative data from 10 different fields of Ki-67 FFPE section of each treatment group. One way ANOVA was performed, and Tukey’s multiple comparison test was performed to determine p values (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Injection, Saline, TUNEL Assay, Immunohistochemistry, Staining, Comparison

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: ZMYND8 is a binding partner of nuclear CD55. ( A , B ) CP70 cells were cultured and cytoplasmic and nuclear proteins were extracted. CD55 protein was immunoprecipitated (IP) from cytoplasmic and nuclear fractions. The immunoprecipitated protein samples were used to run SDS PAGE. The gels were sent for LCMS analysis to detect binding partners of CD55 protein. Spectral counts obtained from LCMS analysis indicated relative abundance of CD55 binding partners. ZMYND8 was identified as the most abundant binding partner of CD55 protein in the nucleus. ( C ) CP70 cells were transduced with empty vector (EV) or CD55, harvested and lysed followed by immunoprecipitation with CD55 and western blot for CD55 and ZMYND8. ( D ) CP70 cells, transduced with empty vector (EV) or CD55 were harvested and lysed followed by immunoprecipitation with ZMYND8 and western blot for ZMYND8 and CD55. ( E ) Expression of ZMYND8 and CD55 in KO cells. ( F ) ZMYND8 was knocked out by CRISPR, and cell proliferation analyzed by Incucyte. ( G ) Cisplatin sensitivity was assayed in CP70 cells. 95% Confidence Interval (CI) is 10.77–12.97. in ZMYND8 KO, 3.97–5.41 in parental cells. ( H ) Cisplatin sensitivity assay. ( I ) CSC frequency assay. Unpaired t test * p < 0.05. ( J ) CP70 cells (CD55 OE, CD55 KO, CD55∆1234, and CD55∆ST) were grown and immunoblot was performed. Quantification of ZMYND8 expression was also performed using image J software. One way ANOVA was performed, and Tukey’s multiple comparison test was performed to determine p values (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001). ( K ) Real time PCR was performed to check ZMYND8 gene expression in CP70 cells. ( L ) Progression free survival in relation to ZMYND8 expression in 1435 HGSOC and endometrioid patients determined using KMPlot. Number at risk, low = 1017 and high = 418. Hazards ratio and Logrank P indicated in the graph. ( M ) Overall survival in relation to ZMYND8 expression in 516 HGSOC and endometrioid patients determined using KMPlot. Number at risk, low = 1140 and high = 692. Hazards ratio and Logrank P indicated in the graph. ( N ) Reciprocal regulation of CD55 and ZMYND8

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Binding Assay, Cell Culture, Immunoprecipitation, SDS Page, Transduction, Plasmid Preparation, Western Blot, Expressing, CRISPR, Sensitive Assay, Software, Comparison, Real-time Polymerase Chain Reaction, Gene Expression

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: Nuclear CD55 associates with PRC2 members and regulates H3K27me3 mark. ( A ) Expression of H3K27Me3 in cytoplasmic and nuclear fractions of CP70 CD55 KO and CP70 CD55 OE cells. Lamin A/C was used as nuclear marker and tubulin was used as cytoplasmic loading control. ( B ) Expression of PRC2 complex members, EZH2, SUZ12, EED, JRID2, AEBP2, and EZH1 in cytoplasmic and nuclear fractions of CP70 CD55 KO and CP70 CD55 OE cells. ( C ) GSEA plot after bulk RNA sequencing in CP70 CD55 KO and OE cells. PRC2 target genes were positively correlated with CD55 overexpression. ( D ) Differential gene expression of PRC2 target genes in OE and KO cells. ( E ) CD55 OE cells were cultured, and nuclear fractions were prepared. ZMYND8 protein was immunoprecipitated followed by immunoblot analysis for EZH2, SUZ12, and ZMYND8. ( F ) Nuclear lysates of OE cells were prepared followed by SUZ12 protein immunoprecipitation and immunoblot analysis of SUZ12, CD55, and EZH2. ( G ) Nuclear fractions were prepared from OE cells followed by immunoprecipitation with EZH2 protein and immunoblot analysis of EZH2, CD55, and SUZ12. Each experiment was performed three times. ( H ) CD55 interacts with ZMYND8 and PRC2 complex to modulate PRC2 target genes in ovarian cancer

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Expressing, Marker, Control, RNA Sequencing, Over Expression, Gene Expression, Cell Culture, Immunoprecipitation, Western Blot

Journal: Molecular Cancer

Article Title: Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

doi: 10.1186/s12943-024-02028-5

Figure Lengend Snippet: CD55 induces CSC activity and chemoresistance in Ovarian Cancers. Nuclear CD55 traffics to the nucleus from the cell surface. The S/T domain of CD55 is necessary for nuclear trafficking. In the nucleus, CD55 binds chromatin and interacts with ZMYND8 and PRC2 members and regulates PRC2 target gene expression. Nuclear CD55 drives epigenetic modifications, self-renewal, and platinum resistance in ovarian cancer cells

Article Snippet: Cell titer glow reagent (Promega), FBS (Atlas Biologicals), anti-CD55 antibody from Proteintech and EMD Millipore, anti-ZMYND antibody (Proteintech), anti-GAPDH antibody (Proteintech), anti-Lamin A/C antibody (Proteintech), anti-α Tubulin antibody (Proteintech), Goat anti-Rabbit IgG Alexa Fluor 488 (Thermo Scientific), and Goat anti-mouse IgG Alexa Fluor 568 (Thermo Scientific) were used in different studies.

Techniques: Activity Assay, Targeted Gene Expression